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There are an estimated 250 million
cases of Plasmodium falciparum malaria every
year, which cost 1–2 million lives. The
majority of serious and fatal cases occur
among children below the age of five
years, as substantial protective immunity is
gradually acquired following repeated
infections. Adolescents and adults there-
fore rarely suffer clinical episodes of
malaria.
Pregnancy-Associated Malaria
Nevertheless, women in such areas
again become highly vulnerable to infec-
tion by P. falciparum parasites when they
get pregnant, especially during a first
pregnancy. This pregnancy-associated re-
appearance of susceptibility is related to
the ability of the parasites to escape pre-
existing clinical immunity by expressing
particular pregnancy-specific antigens on
the surface of infected erythrocytes [1].
These antigens, which appear largely
synonymous with the VAR2CSA member
of the PfEMP1 protein family [2], allow
infected erythrocytes to accumulate on the
maternal side of the placenta. The para-
sites often survive pre-existing immunity
because VAR2CSA expression appears
confined to placenta-sequestering para-
sites, which means that many pregnant
women—particularly primigravidae—do
not possess adequate VAR2CSA-specific
immunity to clear them.
Prenatal Exposure to Malaria
Parasites
Placental parasitemia is associated with
maternal anemia, prematurity, low birth
weight, and excess perinatal morbidity and
mortality [3]. An additional, but much less
studied, consequence of placental parasit-
emia is that many newborns are born with
immune systems that are already primed
because they have been exposed to P.
falciparum antigens in utero. Prenatal
exposure can result in fetal acquisition of
parasite-specific antibody and cytokine
responses that can be measured in the
infant’s lymphocytes at delivery, but may
also lead to tolerance and immunological
anergy at subsequent re-exposure [4].
The time to first parasitemia is generally
shorter in offspring of mothers with
placental P. falciparum infection at delivery
than in offspring of mothers without. This
discrepancy is often interpreted as the
consequence of impaired acquisition of
protective immunity in children exposed
to antigen while in the womb. However, in
all likelihood a multitude of factors
contribute and interact in complex ways,
which are rarely considered in much
detail.
Does Prenatal Exposure Impair
Acquisition of Protective
Immunity?
In this week’s PLoS Medicine, Christo-
pher King and colleagues [5] report results
from a study designed to directly address
the hypothesis that prenatal exposure to
parasite antigens directly affects the risk of
malaria in infancy. The authors recruited
586 pregnant women and their newborn
children from an area of stable transmis-
sion of P. falciparum parasites in coastal
Kenya. Venous and placental blood from
the mothers as well as cord blood from the
babies was examined by microscopy and
PCR for presence of parasites to evaluate
prenatal exposure to parasite antigens.
The authors then tested the parasite
antigen-specific immune reactivity in the
offspring at delivery and every six months
thereafter for the first three years of life.
The antigens examined were parasite
proteins involved in merozoite invasion
of erythrocytes, targets of protective im-
munity, and vaccine candidates. Antigen-
induced responses included lymphocyte
proliferation and cytokine production.
Furthermore, the authors measured plas-
ma levels of IgG with specificity for some
of the antigens used in the in vitro assays of
cellular immunity.
Once all data were collected, the
authors compared the results in three
sub-groups of the children. The first of
these was composed of the 246 ‘‘sensi-
tized’’ children, where cytokine responses
(other than IL-10) could be detected in
antigen-stimulated cord blood cultures.
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Linked Research Article
This Perspective discusses the fol-
lowing new study published in PLoS
Medicine:
Malhotra I, Dent A, Mungai P,
Wamachi A, Ouma JH, Narum DL,
Muchiri E, Tisch DJ, King CL (2009)
Can prenatal malaria exposure pro-
duce an immune tolerant pheno-
type?: A prospective birth cohort
study in Kenya. PLoS Med 6(7):
e1000116. doi:10.1371/journal.
pmed.1000116
In a prospective cohort study of
newborns residing in a malaria
holoendemic area of Kenya, Chris-
topher King and colleagues find a
subset of children born to malaria-
infected women who acquire a
tolerant phenotype, which persists
into childhood and is associated
with increased susceptibility to ma-
larial infection and anemia.
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‘‘not sensitized’’ children, whose cord
blood cells did not produce cytokine
responses despite parasitological evidence
of in utero exposure. Finally, the third sub-
group consisted of the 220 ‘‘not exposed’’
children, where no antigen-induced cord
lymphocyte cytokines were detected, but
where parasitological evidence of prenatal
exposure could not be obtained.
The ‘‘not sensitized’’ children who
appeared to have been tolerized to P.
falciparum antigens before birth were ap-
proximately 40% more likely to become
infected during the follow-up period than
either sensitized or unexposed children. In
contrast to earlier studies [6,7], maternal
parity did not influence the risk of
infection in the children. Parasitemias
tended to be low, and not much different
between groups. Nevertheless, the puta-
tively tolerized children were more anemic
than the other children. In addition,
lymphocytes from the ‘‘not sensitized’’
children were less likely to produce
cytokines such as IFN-c and IL-2 and
more likely to produce IL-10 in response
to antigenic stimulation, particularly in the
second half of the follow-up period.
Similar and high plasma levels of malaria
antigen-specific IgG were detected in all
newborns (due to passive transfer of
maternal IgG across the placenta). As
expected, these levels fell to very low levels
in the second half of the first year, and
then slowly increased during the second
year as the children started to acquire
immunity to the parasites. There were no
obvious differences between the groups of
children with respect to acquisition of
parasite-specific antibodies.
Where From Here?
The authors conclude that their data
show that a sizeable proportion of children
in endemic areas are immunologically
disadvantaged at birth as a consequence
of being exposed to P. falciparum antigens
before birth, and that this is of clinical
importance because it increases their risk
of parasitemia in the first few years of life.
If this is indeed the case, it is of obvious
importance to clinicians and health policy
makers. However, there are issues that
require further study and consideration by
scientists in this field. First of all, it is
intuitively surprising how such a disad-
vantage can persist despite the expected
negative selection pressure against it.
Secondly, it should be considered whether
below average, Th1-type, ‘‘pro-inflamma-
tory’’ cellular immune responses and low-
level parasitemia are in fact adequate
indicators of impaired clinical immunity,
when several studies have shown that
asymptomatic infection actually protects
against clinical diseases episodes, and that
eradication of such infections can be
detrimental [8–10]. Thirdly, only parasit-
emia detectable at parturition was consid-
ered. However, the prevalence of placental
infection peaks in the second trimester,
and undoubtedly many infections with the
potential to affect the immune system of
the fetus have been resolved well before
delivery [11]. Fourthly, the authors chose
to study cytokine responses to ‘‘classical’’
parasite antigens rather than the antibody
responses to the so-called variant surface
antigens, which are important determi-
nants of clinical immunity [12]. Finally,
there are issues related to anti-malarial
drug use and HIV infection that remain
unresolved after the present study.
In conclusion, the study by King et al.
adds significantly to our understanding of
prenatal exposure to P. falciparum antigens.
Hopefully, the study will inspire scientists
in the field to study this complex and
clinically significant issue further.
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